title: Mapping the translational science policy 'valley of death'.
abstract: Translating the knowledge from biomedical science into clinical applications that help patients has been compared to crossing a valley of death because of the many issues that separate the bench from the bedside and threaten to stall progress. But translation is also inhibited by a science policy environment with its own impediments. Mapping these policy impediments give a more complete picture of the valley of death. Stem cell science is one example where success in moving from the bench to the bedside has confronted policy challenges generating difficulties as challenging as those facing scientists and clinicians. We highlight some of the characteristics and challenges of the science policy valley of death common to the U.S. and Europe, illustrate them with a recent example from stem cell science, and describe some promising strategies for traversing the valley.
authors.affiliation: Indiana University Center for Bioethics, 410 West 10th Street, 46202 Indianapolis, USA. emeslin@iu.edu.
authors.forename: Eric M
authors.initials: EM
authors.lastname: Meslin
authors.forename: Alessandro
authors.initials: A
authors.lastname: Blasimme
authors.forename: Anne
authors.initials: A
authors.lastname: Cambon-Thomsen
references.citation: Lancet Glob Health. 2013 Aug;1(2):e64-e65
references.pmid: 25104151
references.citation: Sci Transl Med. 2011 Jul 6;3(90):90cm17
references.pmid: 21734173
references.citation: Clin Transl Sci. 2010 Dec;3(6):316-8
references.pmid: 21167009
references.citation: EMBO Rep. 2009 Jan;10(1):17-20
references.pmid: 19098939
references.citation: Science. 1998 Nov 6;282(5391):1145-7
references.pmid: 9804556
references.citation: JAMA. 2008 Jan 9;299(2):211-3
references.pmid: 18182604
references.citation: PLoS One. 2012;7(3):e31824
references.pmid: 22427809
references.citation: Science. 2012 Sep 7;337(6099):1176-7
references.pmid: 22955820
references.citation: Cell. 2007 Nov 30;131(5):861-72
references.pmid: 18035408
references.citation: N Y Times Web. 1998 Nov 12;:A1, A26
references.pmid: 11648125
references.citation: Stem Cell Rev Rep. 2009 Jun;5(2):82-8
references.pmid: 19521798
references.citation: Science. 2012 May 11;336(6082):673-4
references.pmid: 22582247
references.citation: Global Health. 2011 Feb 24;7:3
references.pmid: 21349182
references.citation: N Engl J Med. 2010 Jul 22;363(4):301-4
references.pmid: 20551152
references.citation: Cell Stem Cell. 2008 Dec 4;3(6):607-9
references.pmid: 19041777
references.citation: Cell. 2013 Jun 6;153(6):1228-38
references.pmid: 23683578
references.citation: Clin Transl Sci. 2012 Jun;5(3):273-80
references.pmid: 22686206
references.citation: Mod Healthc. 2011 Aug 1;41(31):8-9
references.pmid: 21853567
references.citation: Sci Transl Med. 2009 Dec 9;1(10):10cm9
references.pmid: 20368156
references.citation: Heart. 2010 Jun;96(11):815-6
references.pmid: 20478860
references.citation: Nat Rev Drug Discov. 2010 Mar;9(3):203-14
references.pmid: 20168317
references.citation: Regen Med. 2007 May;2(3):301-11
references.pmid: 17511566
references.citation: Nature. 1999 Dec 2;402(6761 Suppl):C81-4
references.pmid: 10591229
references.citation: Genet Med. 2007 Oct;9(10):665-74
references.pmid: 18073579
references.citation: J Law Soc. 2012;39(1):113-30
references.pmid: 22530248
references.citation: Kennedy Inst Ethics J. 2002 Mar;12(1):95-102
references.pmid: 12211268
references.citation: Cell Stem Cell. 2011 Feb 4;8(2):132-5
references.pmid: 21295270